← Human Trials & Peer-Reviewed Studies
A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)
Plain-language guide to PMID 32164767 (2020): double-blind randomized controlled trial study of Relaxin (Serelaxin).
Key Facts
- PMID
- 32164767
- Journal
- Trials
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Gifford FJ et al. (8 authors)
- DOI
- 10.1186/s13063-020-4203-9
What This Study Did, in Plain Language
What Was Tested
Researchers studied Relaxin (Serelaxin) in this randomized controlled trial publication.
In preclinical models, recombinant human relaxin-2 (serelaxin) had anti-fibrotic effects and ameliorated portal hypertension (PH).
Registered on 1 February 2016.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Participants were allocated to serelaxin or placebo in a 3:1 ratio.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Relaxin (Serelaxin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Relaxin (Serelaxin), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Relaxin (Serelaxin) group a baseline to be compared against.
The placebo was matched to serelaxin on appearance and administration protocol to create and maintain blinding.
Secondary endpoints included the change from baseline in hepatic blood flow and systemic haemodynamics (cardiac index, systemic vascular resistance index and aortic pulse wave velocity).
Short-term safety and tolerability of serelaxin were assessed.
What Was Measured
The subject headings attached to it are Hemodynamics, Hypertension, Portal, Liver, Liver Cirrhosis, Portal Pressure, Proof of Concept Study and Recombinant Proteins.
Author keywords: Portal hypertension and Serelaxin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Relaxin (Serelaxin).
Results are reported in around 12 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2020 (Trials), a journal based in England.
More context: the Relaxin (Serelaxin) compound page, all human trials.
Our Notes on the Compound
Relaxin (Serelaxin): A pregnancy hormone that relaxes blood vessels; serelaxin is a recombinant form studied in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.